ESCITALOPRAM VIR PHARMA

AU:B3 N06AG02(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyUK:POM(Prescription only) 4-chloro-N-(2-morpholin-4-ylethyl)benzamide 71320-77-9Y 4235 7428 DB01171Y 4087Y PJ0Y7AZB63 D02561Y CHEBI:83531N ChEMBL86304Y DTXSID9040554 Interactive image Clc1ccc(cc1)C(=O)NCCN2CCOCC2 InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)YKey:YHXISWVBGDMDLQ-UHFFFAOYSA-NY Moclobemide, sold under the brand namesAmira,Aurorix,Clobemix,DepnilandManerixamong others, is areversible inhibitor of monoamine oxidase A(RIMA) drug primarily used to treatdepressionandsocial anxiety.It is not approved for use in the United States,but is approved in other Western countries such as Canada, the United Kingdomand Australia.It is produced by affiliates of theHoffmann–La Rochepharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired andCiplaMedpro's Depnil and Pharma Dynamic's Clorix became available at half the cost. No significant rise in blood pressure occurs when moclobemide is combined with amines such astyramine-containing foods or pressor amine drugs, unlike with the older irreversible and non-selectivemonoamine oxidase inhibitors(MAOIs), which cause a severe rise in blood pressure with such combination.Due to the lack ofanticholinergic,cardiovascular, cognitive and psychomotor impairments moclobemide is advantageous in the elderly as well as those with cardiovascular disease. Moclobemide was first introduced for medical use in 1989.